Policlinico San Pietro Gruppo San Donato
- Address
- lock Available on a paid plan
Policlinico San Pietro Gruppo San Donato - Respiratory Research Center
Policlinico San Pietro Gruppo San Donato is a leading Italian research institution specializing in advanced respiratory disease management and pediatric care. The center demonstrates particular expertise in investigating novel therapeutic approaches for complex airway disorders, with a focus on severe asthma phenotypes in vulnerable patient populations.
- Severe eosinophilic asthma in pediatric and adolescent patients
- Biologic therapies targeting inflammatory pathways in respiratory disease
- Clinical evaluation of asthma exacerbation prevention strategies
The center's research program emphasizes the study of eosinophil-driven inflammation and its impact on asthma control in younger patient populations. By investigating targeted biologic interventions such as benralizumab, Policlinico San Pietro contributes to advancing personalized medicine approaches for children and adolescents with uncontrolled severe asthma, ultimately aiming to reduce exacerbations and preserve long-term lung function in these high-risk patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Policlinico San Pietro Gruppo San Donato
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA) | AstraZeneca AB | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Benralizumab | 1 | Unknown | 2023-06-05 | 2023-06-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.